Background: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, and it has obvious genetic and clinical heterogeneity. Recently, heterozygous truncating variants (tv) have been shown to cause HCM. However, the spectrum of variants and their relationships with the clinical characteristics of Chinese patients with HCM remain to be elucidated.
Methods And Results: Whole-exome sequencing data from 986 patients with HCM and 761 controls without HCM were utilized to analyze variants. Eleven tv were detected in 18 patients with HCM (1.8 %), while no such variants were identified in controls. We also detected 21 rare missense variants in 16 patients with HCM (1.6 %) and 8 controls (1.1 %), respectively. tv were significantly enriched in patients with HCM < 0.001), whereas the prevalence of missense variants was comparable between the HCM and control groups ( = 0.309). Patients with tv exhibited a significantly lower left ventricular outflow tract gradient ( = 0.011) and a higher prevalence of apical HCM (27.8 %; = 0.008).
Conclusions: Our study supports that heterozygous tv, but not missense variants, are a genetic cause of HCM. Patients with HCM carrying tv have a greater likelihood of developing apical HCM.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11252875 | PMC |
http://dx.doi.org/10.1016/j.heliyon.2024.e32786 | DOI Listing |
Phys Eng Sci Med
January 2025
School of Electrical Engineering and Electronic Information, Xihua University, Chengdu, China.
Hypertrophic cardiomyopathy (HCM), including obstructive HCM and non-obstructive HCM, can lead to sudden cardiac arrest in adolescents and athletes. Early diagnosis and treatment through auscultation of different types of HCM can prevent the occurrence of malignant events. However, it is challenging to distinguish the pathological information of HCM related to differential left ventricular outflow tract pressure gradients.
View Article and Find Full Text PDFFront Cardiovasc Med
January 2025
Department of Cardiology, Vayodha Hospitals, Kathmandu, Nepal.
Introduction: Hypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM). Traditional treatments address symptoms but not the underlying disease mechanism, highlighting the need for novel therapies.
View Article and Find Full Text PDFAm Heart J Plus
February 2025
Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Study Objective: Hypertrophic cardiomyopathy (HCM) is the most common genetic myocardial disorder increasingly characterized by concomitant metabolic syndrome. Cardiac rehabilitation (CR) has been shown to improve metabolic parameters in populations with heart failure and myocardial infarction. However, there is a paucity of data on the impact of CR in the HCM population with metabolic syndrome.
View Article and Find Full Text PDFEur Heart J Cardiovasc Imaging
January 2025
Heart Institute. Department of Cardiology. Cardiovascular Imaging Unit. Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
Aims: How the underlying etiology and pathophysiology of left ventricular (LV) hypertrophy affects LA remodeling and function remains unexplored. The present study aims to investigate the influence of various hypertrophic phenotypes on LA remodeling and function.
Methods And Results: Patients with LV hypertrophy who underwent cardiac magnetic resonance (CMR) were compared to a control group.
CPT Pharmacometrics Syst Pharmacol
January 2025
Huashan Hospital, Fudan University, Shanghai, China.
Mavacamten is a cardiac myosin inhibitor for adults with obstructive hypertrophic cardiomyopathy (HCM). Dose optimization is performed 4 weeks after starting mavacamten, guided by periodic echo measurements of Valsalva left ventricular outflow tract gradient (VLVOTg) and left ventricular ejection fraction (LVEF). Previously, a population pharmacokinetic (PPK) model was developed and exposure-response (E-R) of VLVOTg (efficacy) and LVEF (safety) was used to identify the mavacamten titration regimen with the optimal benefit/risk ratio, now included in the US prescribing information.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!